摘要
目的 :探讨DNA拓扑异构酶Ⅱ (TopoⅡ )在增生性细胞中的表达情况以及在肿瘤诊断中的价值。 方法 :应用S P免疫组化法检测 10例良性扁桃体组织、8例垂体腺瘤、5例乳腺癌、16例胃癌和 5例肾癌及其周围正常组织中TopoⅡ的表达情况 ,并与常用的细胞增生标记物P5 3、Ki 6 7和增殖细胞核抗原 (PCNA)进行比较。 结果 :与正常组织细胞比较 ,TopoⅡ在各种肿瘤中的表达显著增高 (乳腺癌组P <0 .0 0 0 1、胃癌组P <0 .0 1、肾癌组P <0 .0 5 )。TopoⅡ标记指数 (LI)与Ki 6 7LI有显著相关性。胃癌组TopoⅡLI与年龄、性别和临床分级、分期无关 (P>0 .0 5 )。垂体腺瘤组TopoⅡLI与年龄和性别无关 (P >0 .0 5 )。在扁桃体淋巴组织中 ,TopoⅡ主要在滤泡基底暗区表达。 结论 :TopoⅡ可能成为反映细胞增生程度较客观的指标 ,特别在胃肠道、乳腺、肾脏肿瘤诊断及预后判断中有比较重要的意义。
Objective:To investigate the relationship between the expression of DNA topoisomerace Ⅱ (TopoⅡ) and cell proliferation of cancers. Methods:The expresson of TopoⅡ,Ki-67,P53 and PCNA in 10 cases of chronic tonsillitis and 34 patients with cancers (8 pituitary adenomas, 5 breast carcinomas,16 gastric carcinomas and 5 renal cell carcinomas) were examined by immunohistochemistory S-P method using monoclonal antibodys to their proteins. Results:Significant difference of TopoⅡlabeling index(LI) was noticed in gastric carcinomas and normal stomachs (P<0.05). TopoⅡ LI exhibited close correlation with Ki-67 LI in breast carcinomas (P<0.000 1), gastric carcinomas (P<0.01) and renal cell carcinomas (P<0.05). Topo ⅡLI had no significant correlation with the age, sex, clinical grades and stages (P>0.05) in gastric carcinomas. Topo Ⅱ LI had no significant correlation with the age, sex (P>0.05) in pituitary adenomas. Conclusion:TopoⅡmight be an objective index for demonstrating cell proliferation.
出处
《医学研究生学报》
CAS
2004年第3期240-242,245,F003,共5页
Journal of Medical Postgraduates
